** Shares of drug developer Lipocine up 6.19% at $5.5 in premarket trading
** Administration of Oral brexanolone, co's drug for treating post-partum depression, was consistent with therapies effective in managing depression, anxiety, tremors, and seizures
**Oral brexanolone was well-tolerated in the Phase 1 study, with a safety profile consistent with previous clinical studies
** As of last close stock up 85.30% YTD
(Reporting by Khusbu Jena)
((Khusbu.Jena@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.